Huang Nanqu, Huang Wendi, Wu Jingjing, Long Sheng, Luo Yong, Huang Juan
National Drug Clinical Trial Institution, The First People's Hospital of Zunyi, Third Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Cloud Computing Division, Jiangsu Hoperun Software Co., Ltd., Nanjing, Jiangsu, China.
Front Pharmacol. 2024 Jun 21;15:1426300. doi: 10.3389/fphar.2024.1426300. eCollection 2024.
The drug development process is poised for significant transformation due to the rapid advancement of modern biological and information technologies, such as artificial intelligence (AI). As these new technologies and concepts infiltrate every stage of drug development, the efficiency and success rate of research and development are expected to improve substantially. Traditional Chinese medicine (TCM), a time-honored therapeutic system encompassing herbal medicine, acupuncture, and qigong, will also be profoundly impacted by these advancements. Over the next decade, Traditional Chinese medicine research will encounter both opportunities and challenges as it integrates with modern technologies and concepts. By 2035, TCM is anticipated to merge with modern medicine through a more contemporary and open research and development model, providing substantial support for treating a broader spectrum of diseases.
由于人工智能（AI）等现代生物技术和信息技术的迅速发展，药物研发过程正面临重大变革。随着这些新技术和概念渗透到药物研发的各个阶段，预计研发效率和成功率将大幅提高。传统中医（TCM）是一个历史悠久的治疗体系，涵盖草药、针灸和气功，也将受到这些进步的深刻影响。在未来十年，传统中医研究在与现代技术和概念融合的过程中将面临机遇和挑战。到2035年，预计传统中医将通过更现代、开放的研发模式与现代医学融合，为治疗更广泛的疾病提供有力支持。
Zotero 插件